



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

# Ocaliva (obeticholic acid)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:		* Date of Birth:
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
<b>Urgency:</b> <input type="checkbox"/> Standard <span style="margin-left: 200px;"><input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)</span>					
<b>Medication requested:</b> Ocaliva 5mg: <input type="checkbox"/> <span style="margin-left: 150px;">Ocaliva 10mg: <input type="checkbox"/></span> <span style="margin-left: 150px;">ICD10:</span>  Directions for use: <span style="margin-left: 150px;">Quantity:</span> <span style="margin-left: 150px;">Duration of therapy:</span>  If using more than 1 tablet per day, please provide clinical rationale for this dosing, including reason why patient is taking 2x5mg tablets versus 1x10mg, if applicable:					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span>					
<b>Clinical Information:</b> <b>**This drug requires supportive documentation (i.e. genetic testing, chart notes, lab/test results, etc). Supportive documentation for all answers must be attached with this request.**</b>					
Is this a new start or continuation of therapy? <input type="checkbox"/> new start <input type="checkbox"/> continued therapy (if continued therapy) Does your patient have documented beneficial clinical response to Ocaliva? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span> <b>Please provide documentation to support.</b>					
Does your patient have any of the following? Supportive documentation must be provided. <input type="checkbox"/> history of elevated alkaline phosphatase (ALP) for at least 6 months <input type="checkbox"/> presence of antimitochondrial antibody (AMA) OR, if AMA is negative or in low titer (less than 1:80), PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex]) <input type="checkbox"/> evidence of PBC on liver biopsy <input type="checkbox"/> none of the above					
Has your patient ever been treated with ursodiol (Actigall, Urso, Urso Forte)? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span> (if no ursodiol) Does your patient have a contraindication per FDA label to ursodiol therapy? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span> (if yes) What is the contraindication?					
(if ursodiol) Was your patient treated for at least 6 months with ursodiol? <input type="checkbox"/> Yes <input type="checkbox"/> No, due to patient didn't tolerate ursodiol <input type="checkbox"/> No, due to another reason (if less than 6 months) What was the intolerance or reason that your patient stopped ursodiol? <b>Please provide chart notes to document this.</b> (if 6 or more months) Did your patient have a good (adequate) response to ursodiol therapy? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span> (if no) Which of the following was evidence of your patient's inadequate response to ursodiol therapy? <input type="checkbox"/> inadequate reduction of alkaline phosphatase (ALP) (greater than or equal to 1.67 times the upper limit of normal) <input type="checkbox"/> inadequate reduction of total bilirubin (greater than the upper limit of normal but less than two times the upper limit of normal)					

- evidence of disease progression on biopsy  
 other  
(if other) Please explain.

(if no) Will your patient be using Ocaliva in combination with ursodiol?

**Additional Pertinent Information:** *(please include clinical support for the use of this drug in your patient, including complications of disease):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at: [www.covermymeds.com/main/prior-authorization-forms/cigna/](http://www.covermymeds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.**

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

V111516

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005